Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068369 | 0.84 | SMN1; SMN2 (0.38) | BTKKMT2ASMN1; SMN2 | |
| SCHEMBL21217318 | 0.83 | CHRM2 (0.30) | — | |
| SCHEMBL25993364 | 0.71 | CHRM2 (0.32) | — | |
| SCHEMBL20068385 | 0.69 | BTK (0.39) | BTKHSD17B10KMT2ASMN1; SMN2LMNA | |
| SCHEMBL23798668 | 0.68 | BTK (0.38) | BTKHSD17B10KMT2ASMN1; SMN2LMNA | |
| SCHEMBL22310390 | 0.68 | BTK (0.38) | BTKHSD17B10KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1072603 | 0.67 | HRH3 (0.46) | BTKHSD17B10KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10328238 | 0.67 | HRH3 (0.46) | BTKHSD17B10KMT2ASMN1; SMN2LMNA | |
| SCHEMBL5264559 | 0.67 | HRH3 (0.46) | BTKHSD17B10KMT2ASMN1; SMN2LMNA | |
| SCHEMBL23420382 | 0.64 | LMNA (0.43) | BTKHSD17B10KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968177-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190233374-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-01 | — | — | US | disclosed |
| WO-2018071314-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968177-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | BTK 1210/4885HSD17B10 324/4885KMT2A 3366/4885 |
| US-20190233374-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | BTK 1716/4885HSD17B10 622/4885KMT2A 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.